Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fused thiophene derivatives as MEK inhibitors.
Laing VE, Brookings DC, Carbery RJ, Simorte JG, Hutchings MC, Langham BJ, Lowe MA, Allen RA, Fetterman JR, Turner J, Meier C, Kennedy J, Merriman M. Laing VE, et al. Among authors: brookings dc. Bioorg Med Chem Lett. 2012 Jan 1;22(1):472-5. doi: 10.1016/j.bmcl.2011.10.105. Epub 2011 Nov 6. Bioorg Med Chem Lett. 2012. PMID: 22119475
Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors.
Holdsworth G, Slocombe P, Doyle C, Sweeney B, Veverka V, Le Riche K, Franklin RJ, Compson J, Brookings D, Turner J, Kennedy J, Garlish R, Shi J, Newnham L, McMillan D, Muzylak M, Carr MD, Henry AJ, Ceska T, Robinson MK. Holdsworth G, et al. J Biol Chem. 2012 Aug 3;287(32):26464-77. doi: 10.1074/jbc.M112.350108. Epub 2012 Jun 13. J Biol Chem. 2012. PMID: 22696217 Free PMC article.
Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3Kδ.
Allen RA, Brookings DC, Powell MJ, Delgado J, Shuttleworth LK, Merriman M, Fahy IJ, Tewari R, Silva JP, Healy LJ, Davies GCG, Twomey B, Cutler RM, Kotian A, Crosby A, McCluskey G, Watt GF, Payne A. Allen RA, et al. Among authors: brookings dc. J Pharmacol Exp Ther. 2017 Jun;361(3):429-440. doi: 10.1124/jpet.116.237347. Epub 2017 Apr 25. J Pharmacol Exp Ther. 2017. PMID: 28442583
Discovery of a Potent, Orally Bioavailable PI4KIIIβ Inhibitor (UCB9608) Able To Significantly Prolong Allogeneic Organ Engraftment in Vivo.
Reuberson J, Horsley H, Franklin RJ, Ford D, Neuss J, Brookings D, Huang Q, Vanderhoydonck B, Gao LJ, Jang MY, Herdewijn P, Ghawalkar A, Fallah-Arani F, Khan AR, Henshall J, Jairaj M, Malcolm S, Ward E, Shuttleworth L, Lin Y, Li S, Louat T, Waer M, Herman J, Payne A, Ceska T, Doyle C, Pitt W, Calmiano M, Augustin M, Steinbacher S, Lammens A, Allen R. Reuberson J, et al. J Med Chem. 2018 Aug 9;61(15):6705-6723. doi: 10.1021/acs.jmedchem.8b00521. Epub 2018 Jul 19. J Med Chem. 2018. PMID: 29952567
4-(1,3-Thiazol-2-yl)morpholine derivatives as inhibitors of phosphoinositide 3-kinase.
Alexander R, Balasundaram A, Batchelor M, Brookings D, Crépy K, Crabbe T, Deltent MF, Driessens F, Gill A, Harris S, Hutchinson G, Kulisa C, Merriman M, Mistry P, Parton T, Turner J, Whitcombe I, Wright S. Alexander R, et al. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4316-20. doi: 10.1016/j.bmcl.2008.06.076. Epub 2008 Jun 28. Bioorg Med Chem Lett. 2008. PMID: 18625552
Peptide deformylase inhibitors with activity against respiratory tract pathogens.
East SP, Beckett RP, Brookings DC, Clements JM, Doel S, Keavey K, Pain G, Smith HK, Thomas W, Thompson AJ, Todd RS, Whittaker M. East SP, et al. Among authors: brookings dc. Bioorg Med Chem Lett. 2004 Jan 5;14(1):59-62. doi: 10.1016/j.bmcl.2003.10.013. Bioorg Med Chem Lett. 2004. PMID: 14684298
Novel nucleotide triphosphates as potent P2Y2 agonists.
Brookings D, Davenport RJ, Davis J, Galvin FC, Lloyd S, Mack SR, Owens R, Sabin V, Wynn J. Brookings D, et al. Bioorg Med Chem Lett. 2007 Jan 15;17(2):562-5. doi: 10.1016/j.bmcl.2006.09.017. Epub 2006 Sep 29. Bioorg Med Chem Lett. 2007. PMID: 17011188
Corrigendum: An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis.
Vugler A, O'connell J, Nguyen MA, Weitz D, Leeuw T, Hickford E, Verbitsky A, Ying X, Rehberg M, Carrington B, Merriman M, Moss A, Nicolas JM, Stanley P, Wright S, Bourne T, Foricher Y, Zhu Z, Brookings D, Horsley H, Heer J, Schio L, Herrmann M, Rao S, Kohlmann M, Florian P. Vugler A, et al. Front Pharmacol. 2024 Oct 16;15:1479557. doi: 10.3389/fphar.2024.1479557. eCollection 2024. Front Pharmacol. 2024. PMID: 39478966 Free PMC article.
An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis.
Vugler A, O'Connell J, Nguyen MA, Weitz D, Leeuw T, Hickford E, Verbitsky A, Ying X, Rehberg M, Carrington B, Merriman M, Moss A, Nicholas JM, Stanley P, Wright S, Bourne T, Foricher Y, Zhu Z, Brookings D, Horsley H, Heer J, Schio L, Herrmann M, Rao S, Kohlmann M, Florian P. Vugler A, et al. Front Pharmacol. 2022 Nov 16;13:1037983. doi: 10.3389/fphar.2022.1037983. eCollection 2022. Front Pharmacol. 2022. PMID: 36467083 Free PMC article.